KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deffered Revenue: 2010-2025

Historic Non-Current Deffered Revenue for Arbutus Biopharma (ABUS) over the last 7 years, with Mar 2025 value amounting to $2.9 million.

  • Arbutus Biopharma's Non-Current Deffered Revenue was N/A to $2.9 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2024, which is N/A change from last year.
  • Per Arbutus Biopharma's latest filing, its Non-Current Deffered Revenue stood at $2.9 million for Q1 2025, which was down 0.00% from $2.9 million recorded in Q4 2024.
  • In the past 5 years, Arbutus Biopharma's Non-Current Deffered Revenue ranged from a high of $15.6 million in Q1 2022 and a low of $2.9 million during Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $2.9 million (2025), whereas its average is $3.0 million.
  • Data for Arbutus Biopharma's Non-Current Deffered Revenue shows a maximum YoY crashed of 78.85% (in 2023) over the last 5 years.
  • Over the past 4 years, Arbutus Biopharma's Non-Current Deffered Revenue (Quarterly) stood at $6.0 million in 2022, then slumped by 78.85% to $3.3 million in 2023, then reached $2.9 million in 2024, then reached $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q1 2025, $2.9 million for Q4 2024, and $3.3 million during Q1 2023.